HEALTHCARE SERVICES GROUP, INC. (HCSG): what the price requires

At today's price, HEALTHCARE SERVICES GROUP, INC. (HCSG) is priced for +18.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/HCSG

Headline

FieldValue
TickerHCSG
CompanyHEALTHCARE SERVICES GROUP, INC.
Current price$24.02/sh
CompositionEnvironmental Services 45% / Dietary 55%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed3.9%
Operating margin today4.0%
Margin compression implied-0.1pp
Implied growth18.5%
Multiple paid20x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.5% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7pp.

How unusual the bet is: elevated

ReferenceValue
vs own history+3.41σ
cohort percentile (of 113 peers)45
sustained it ~5 years at this level42%
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and growth-DCF value, while asset-based/relative-multiple land below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.95x4expensive
Earnings1.01x3expensive
Relative1.83x3expensive
Growth0.83x3justifies

Families that justify the price: Earnings, Growth Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$47.010.51xyesFCF base $0.2B, growth 6% (input: historical growth), terminal g 4.0%, WACC 9.2%, 5yr projection
DCF Exit MultipleGrowth$29.050.83xyesExit EV/EBITDA: 92.9x / 94.9x / 96.9x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$13.141.83xyesP/E 18x (static sector reference · 2026-04), scenarios: 15.1x / 18.0x / 20.9x (bear / base = reference held flat / bull), EV/EBITDA 26.4x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$10.332.32xyesBV/sh $7.23, ROE (TTM) 13.2%, ke 9.3%
Two-Stage Excess ReturnAsset$12.241.96xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$18.771.28xyesRev $1.9B, growth 6% (input: historical growth; tapered), Terminal P/S: 0.8x / 0.9x / 1.1x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAsset$12.651.90xyesBV $7.23 + 5yr PV of (ROE (TTM) 13.2% − Kₑ 9.3%) × BV; BV grows 8.6%/yr
Graham NumberAsset$12.431.93xyes√(22.5 × EPS $0.95 × BVPS $7.23) — Graham's conservative floor
EV/EBITDA RelativeRelative$4.535.30xyesEBITDA $0.02B × sector EV/EBITDA 12.0x
FCF YieldEarnings$25.410.95xyesFCF $155.7M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$23.731.01xyesSBC-adj FCF $0.14B (FCF $0.16B − SBC $0.01B) capitalized at Kₑ
Ben Graham FormulaEarnings$0.8030.02xyesEPS $0.95 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAssetno
P/Sales SectorRelative$65.180.37xyesRevenue $1.85B × sector P/S 2.5x
PEG Fair ValueRelativeno
Earnings YieldEarnings$10.272.34xyesEPS $0.95 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net cash$178.6m
Net debt / NOPAT (after-tax)-3.21x (net cash)
Net debt / operating income (pre-tax)-2.42x (net cash)
Share count CAGR (buyback)-1.1%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The first thing to understand about HCSG is how far the price sits above what most valuation methods will support, and why the two methods that do reach it matter more than the rest. The asset-value and peer-multiple lenses read the stock as expensive against a thin operating margin; the earnings-power and growth-oriented cash-flow methods reach the price because they credit the cash the business actually throws off rather than the slim reported margin. For a services company that runs at a 4% operating margin by design, cash generation is the right lens, and HCSG converts its modest margin into real free cash flow: operating cash flow was $43.7 million in the first quarter of 2026.

The business itself is sticky in a way the margin understates. HCSG provides environmental services and dietary management to roughly 1,600 facilities, embedding its own management personnel inside customer operations to oversee "various cost and quality" functions alongside the facility's own staff. Once a nursing home outsources its kitchen and housekeeping to HCSG and the company's managers are running those departments day to day, switching back or to a competitor is disruptive and rarely worth the trouble. That is the moat: not pricing power, but the operational entanglement that produces high retention and steady, contracted revenue.

HCSG carries no debt, ended the quarter with $214.6 million in cash and marketable securities, and has its full $300 million revolver undrawn. Net income rose to $26.1 million from $17.2 million a year earlier, with diluted EPS up to $0.37 from $0.23, and adjusted EBITDA margin improved to 8.4%. Management is returning capital, repurchasing $24 million of stock in the quarter and shrinking the share count. A debt-free, cash-generative, high-retention services business with improving profitability and an active buyback is the kind of compounding the cash-flow methods see and the asset-based ones miss.

Bear Case

The threat to HCSG is not a flashy competitor but the slow erosion of the economics that make outsourcing attractive in the first place. The company sells a service that a nursing home could, in principle, bring back in-house, and the value proposition rests on HCSG running dining and housekeeping more cheaply and more compliantly than the facility can itself. When labor costs rise across the whole sector, that arbitrage narrows: HCSG's own people cost more, and the customer's calculus on whether to outsource shifts. Management itself flagged a cautious cost outlook, aiming to hold cost of services near 86% of revenue, which leaves only a thin sliver of operating margin and almost no room to absorb a wage shock. A 4% operating margin is a business with very little cushion.

The deeper risk is who pays the bills. HCSG does not bill the government directly, but its filing is clear that its "customers receive" government reimbursement, and that reimbursement is what funds the facilities that pay HCSG. The company carries a $149.7 million allowance for doubtful accounts and notes receivable, a number that speaks for itself: a meaningful slice of what HCSG bills, it does not expect to fully collect, because its long-term-care customers operate on thin margins of their own and some do not survive. A change in Medicaid reimbursement, the lifeblood of the skilled-nursing sector, would pressure the customers and therefore HCSG's collections directly.

The valuation leaves no room for any of this to go wrong. At about $23 (June 27, 2026) the price implies company-wide operating growth around 17% a year for five years, a pace that runs well above what HCSG has actually delivered. This is a low-single-digit revenue grower being priced for high-teens profit growth, and history says only about 45% of comparable fast-growers sustained that pace even five years. The cash flow is real and the balance sheet is clean, but the price is asking a stable, slow-growing services business to accelerate sharply, and the customer credit overhang makes that acceleration harder, not easier.

Valuation

At about $22.92 HCSG trades near 19 times company-wide operating income, which inverts into an assumption of roughly 17% annual operating-profit growth sustained for five years. That is a demanding pace for a company whose revenue grows in the low single digits, and it runs well above what HCSG has actually delivered, which is why the priced-in assumption reads as elevated. The stretch is the rate itself, not just its duration.

The methods divide on the same fault line that runs through most thin-margin services businesses. The asset-value and peer-multiple lenses, which key off book value and a sector earnings multiple, read the stock as expensive because HCSG's reported operating margin near 4% looks meager against its market value. The earnings-power and growth-oriented cash-flow methods reach the price, because they value the cash the business generates rather than the slim accounting margin. The right read for this kind of company leans toward the cash lens: HCSG's free cash flow comfortably exceeds what its reported margin would suggest, and the business is a cash converter more than a margin story. But the spread between the two camps is wide, and it is the market paying up for the cash flow while the static measures flag the price as full.

Solvency is the unambiguous strength and the reason the downside is bounded. HCSG carries no debt, holds roughly $214.6 million in cash and marketable securities, and has its entire $300 million revolver available. The share count has been edging lower on buybacks. Standard leverage and coverage math barely applies to a company with no borrowings; the relevant solvency fact is the customer-credit exposure, the $149.7 million doubtful-accounts allowance that sits on the asset side rather than the liability side. What a buyer underwrites at this price is a clean balance sheet and reliable cash conversion, set against a growth assumption that exceeds the company's track record and a customer base whose ability to pay depends on government reimbursement.

Catalysts

Healthcare Services Group's first quarter of 2026 showed steady improvement: revenue of $462.8 million, up 3.4% year over year, net income of $26.1 million against $17.2 million a year earlier, and diluted EPS of $0.37 versus $0.23. Adjusted EBITDA margin improved to 8.4%, driven by high client retention and new client wins. The cause behind the cleaner result was operating execution rather than acceleration: this is a low-single-digit revenue grower whose earnings leverage comes from holding the cost of services near its 86% target.

Cash generation and capital return were the standout. Operating cash flow was $43.7 million, supporting cash and marketable securities of $214.6 million with no draw on the $300 million revolver, and HCSG repurchased $24 million of stock in the quarter. The buyback pace and the cash conversion are the metrics that matter most for a thin-margin services business.

The forward variables to watch are cash collections against the large doubtful-accounts allowance, the trajectory of labor costs that determine whether the cost of services stays near 86%, and any change to the government-reimbursement environment for skilled-nursing facilities, which flows through to HCSG's customers and therefore its collections.

Peer Cohorts (Per Segment, With Filing Citations)

Environmental Services (EVS / Housekeeping & Laundry) (reported)

Dietary (Dining & Nutrition) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

HCSG FY2025 10-K · HCSG Q1 2026 results, April 2026 · HCSG Q1 2026 earnings call, April 2026 · HCSG Q1 2026 earnings release, April 2026

View the full interactive HCSG report on boothcheck